FDA budget not in stone yet

It's never enough. The Alliance for a Stronger FDA is "disappointed" in the president's 23 percent budget increase request and will seek to increase it from tax revenues, which are a shrinking source of FDA funds. User fees, by contrast, have mushroomed to $1.5 billion for 2011--up from a mere $369 million in 2006. Article

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.